Filter by:
Revita
DDW, May 2021
Changes in Incretins Bile acids and the Microbiome after duodenal mucosal resurfacing in patients with Type 2 Diabetes
Meiring, et al. presented at Digestive Disease Week (DDW) 2021, Virtual, May 2021
Revita
Gut, January 2021.
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
Mingrone, et al.
Revita
Gastrointestinal Endoscopy, December 2020.
Duodenal mucosal resurfacing combined with GLP-1RA to discontinue insulin in type 2 diabetes: a feasibility study
van Baar, et al.
Revita
UEG, 2020.
Duodenal mucosal resurfacing combined with GLP-1RA may eliminate insulin treatment in type 2 diabetes while improving glycaemic control and metabolic health
Meirling, et al. presented at United European Gastroenterology Week 2020. Virtual, October 2020.
Revita
Endoscopy International Open; 08: E1683–E1689, October 2020.
Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitus
van Baar, et al.
Revita
ISMRM & SMRT, 2020.
Proton-density fat fraction-derived R2* liver iron concentration – an exploratory study of Revita-2 phase II trial data
Chouhan, et al. presented at ISMRM & SMRT Virtual Conference & Exhibition. Virtual, August 2020.
Revita
ENDO, June 2020.
Mixed-meal tolerance test (MMTT) results from REVITA-2, the first randomized, sham-controlled, double-blind, prospective, multicenter study of duodenal mucosal resurfacing (DMR) safety and efficacy in patients with suboptimally controlled type 2 diabetes (T2D)
Hopkins, et al. presented at Endocrine Online 2020 (ENDO). Virtual, June 2020.
Revita
ADA, 2020.
Durable Glycemic Improvements After Duodenal Mucosal Resurfacing (DMR) in Patients with Type 2 Diabetes (T2D): 48-week Results From the REVITA-2 European Cohort
Mingrone, et al. presented poster at 80th American Diabetes Association Scientific Sessions (ADA) Virtual, June 2020.
Revita
ESGAR, 2020.
MRI liver proton density fat fraction in patients with the type 2 diabetes mellitus following treatment with Duodenal Mucosal Resurfacing – results from a randomised, double-blind, sham-controlled, prospective, multicenter study
Chouhan, et al. presented poster at European Society of Gastrointestinal and Abdominal Radiology 2020 Virtual Congress (ESGAR). Amsterdam, The Netherlands, May 2020.